Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Nanomaterial Delivery Systems for mRNA Vaccines.

Literature DB >> 33478109

Nanomaterial Delivery Systems for mRNA Vaccines.

Michael D Buschmann¹, Manuel J Carrasco¹, Suman Alishetty¹, Mikell Paige², Mohamad Gabriel Alameh³, Drew Weissman⁴.

Abstract

The recent success of mRNA vaccines in SARS-CoV-2 clinical trials is in part due to the development of lipid nanoparticle delivery systems that not only efficiently express the mRNA-encoded immunogen after intramuscular injection, but also play roles as adjuvants and in vaccine reactogenicity. We present an overview of mRNA delivery systems and then focus on the lipid nanoparticles used in the current SARS-CoV-2 vaccine clinical trials. The review concludes with an analysis of the determinants of the performance of lipid nanoparticles in mRNA vaccines.

Entities: CellLine Chemical Disease Gene Species

Keywords: SARS-CoV-2; ionizable lipid; lipid nanoparticle; mRNA; vaccine

Year: 2021 PMID： 33478109 PMCID： PMC7836001 DOI： 10.3390/vaccines9010065

Source DB: PubMed Journal: Vaccines (Basel) ISSN： 2076-393X

142 in total

1. In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies.

Authors: I Hoerr; R Obst; H G Rammensee; G Jung
Journal: Eur J Immunol Date: 2000-01 Impact factor: 5.532

Review 2. The physiology of the lymphatic system.

Authors: M A Swartz
Journal: Adv Drug Deliv Rev Date: 2001-08-23 Impact factor: 15.470

3. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA.

Authors: Katalin Karikó; Michael Buckstein; Houping Ni; Drew Weissman
Journal: Immunity Date: 2005-08 Impact factor: 31.745

4. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability.

Authors: Katalin Karikó; Hiromi Muramatsu; Frank A Welsh; János Ludwig; Hiroki Kato; Shizuo Akira; Drew Weissman
Journal: Mol Ther Date: 2008-09-16 Impact factor: 11.454

5. Protein expression from exogenous mRNA: uptake by receptor-mediated endocytosis and trafficking via the lysosomal pathway.

Authors: Christina Lorenz; Mariola Fotin-Mleczek; Günter Roth; Christina Becker; Thanh Chau Dam; Wouter P R Verdurmen; Roland Brock; Jochen Probst; Thomas Schlake
Journal: RNA Biol Date: 2011-07-01 Impact factor: 4.652

Review 6. mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases.

Authors: Giulietta Maruggi; Cuiling Zhang; Junwei Li; Jeffrey B Ulmer; Dong Yu
Journal: Mol Ther Date: 2019-02-07 Impact factor: 11.454

7. Selective targeting of nanomedicine to inflamed cerebral vasculature to enhance the blood-brain barrier.

Authors: Oscar A Marcos-Contreras; Colin F Greineder; Raisa Yu Kiseleva; Hamideh Parhiz; Landis R Walsh; Viviana Zuluaga-Ramirez; Jacob W Myerson; Elizabeth D Hood; Carlos H Villa; Istvan Tombacz; Norbert Pardi; Alecia Seliga; Barbara L Mui; Ying K Tam; Patrick M Glassman; Vladimir V Shuvaev; Jia Nong; Jacob S Brenner; Makan Khoshnejad; Tom Madden; Drew Weissmann; Yuri Persidsky; Vladimir R Muzykantov
Journal: Proc Natl Acad Sci U S A Date: 2020-01-31 Impact factor: 11.205

8. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms.

Authors: Akin Akinc; William Querbes; Soma De; June Qin; Maria Frank-Kamenetsky; K Narayanannair Jayaprakash; Muthusamy Jayaraman; Kallanthottathil G Rajeev; William L Cantley; J Robert Dorkin; James S Butler; Liuliang Qin; Timothy Racie; Andrew Sprague; Eugenio Fava; Anja Zeigerer; Michael J Hope; Marino Zerial; Dinah W Y Sah; Kevin Fitzgerald; Mark A Tracy; Muthiah Manoharan; Victor Koteliansky; Antonin de Fougerolles; Martin A Maier
Journal: Mol Ther Date: 2010-05-11 Impact factor: 11.454

9. Quantitating Endosomal Escape of a Library of Polymers for mRNA Delivery.

Authors: Yuhang Jiang; Qiao Lu; Yongheng Wang; Emily Xu; Alison Ho; Priya Singh; Yifei Wang; Zhaozhong Jiang; Fan Yang; Gregory T Tietjen; Peter Cresswell; W Mark Saltzman
Journal: Nano Lett Date: 2020-01-31 Impact factor: 12.262

10. An mRNA Vaccine against SARS-CoV-2 - Preliminary Report.

Authors: Lisa A Jackson; Evan J Anderson; Nadine G Rouphael; Paul C Roberts; Mamodikoe Makhene; Rhea N Coler; Michele P McCullough; James D Chappell; Mark R Denison; Laura J Stevens; Andrea J Pruijssers; Adrian McDermott; Britta Flach; Nicole A Doria-Rose; Kizzmekia S Corbett; Kaitlyn M Morabito; Sijy O'Dell; Stephen D Schmidt; Phillip A Swanson; Marcelino Padilla; John R Mascola; Kathleen M Neuzil; Hamilton Bennett; Wellington Sun; Etza Peters; Mat Makowski; Jim Albert; Kaitlyn Cross; Wendy Buchanan; Rhonda Pikaart-Tautges; Julie E Ledgerwood; Barney S Graham; John H Beigel
Journal: N Engl J Med Date: 2020-07-14 Impact factor: 91.245

83 in total

Review 1. Strategies to deliver RNA by nanoparticles for therapeutic potential.

Authors: Alysia Cox; Siyoung A Lim; Eun Ji Chung
Journal: Mol Aspects Med Date: 2021-08-05

2. The Possible Role of Sex As an Important Factor in Development and Administration of Lipid Nanomedicine-Based COVID-19 Vaccine.

Authors: Elisabetta Vulpis; Francesca Giulimondi; Luca Digiacomo; Alessandra Zingoni; Reihaneh Safavi-Sohi; Shahriar Sharifi; Giulio Caracciolo; Morteza Mahmoudi
Journal: Mol Pharm Date: 2021-05-13 Impact factor: 4.939

Review 3. Insights into Antibody-Mediated Alphavirus Immunity and Vaccine Development Landscape.

Authors: Anthony Torres-Ruesta; Rhonda Sin-Ling Chee; Lisa F P Ng
Journal: Microorganisms Date: 2021-04-22

Review 4. mRNA-Based Vaccines.

Authors: Frank Kowalzik; Daniel Schreiner; Christian Jensen; Daniel Teschner; Stephan Gehring; Fred Zepp
Journal: Vaccines (Basel) Date: 2021-04-15